Study investigates the relationship between dietary inflammatory index and stroke risk in US adults

Bris­tol My­ers Squibb will buy CNS drug­mak­er Karuna Ther­a­peu­tics for cash in a deal val­ued at $14 bil­lion, the com­pa­nies an­nounced Fri­day morn­ing. The move

As­traZeneca ar­gued in court on Fri­day that the gov­ern­ment’s rules around which drugs may be ex­empt from Medicare price ne­go­ti­a­tions un­der the In­fla­tion Re­duc­tion Act